BTZ-043   Click here for help

GtoPdb Ligand ID: 13034

Synonyms: BTZ-10526043 | MMV676603
Compound class: Synthetic organic
Comment: BTZ-043 is the lead from a novel class of benzothiazinone compounds with antimycobacterial activity [1], that is is under clinical evaluated as a treatment for tuberculosis (TB). It is an inhibitor of decaprenylphosphoryl-beta-D-ribose oxidase (DprE1), an essential mycobacterial cell wall biosynthesis enzyme [1-3].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 119.57
Molecular weight 431.39
XLogP 2.94
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C[C@H]1COC2(CCN(CC2)C3=NC(=O)C4=CC(=CC(=C4S3)[N+](=O)[O-])C(F)(F)F)O1
Isomeric SMILES C[C@H]1COC2(O1)CCN(CC2)C3=NC(=O)C4=C(S3)C(=CC(=C4)C(F)(F)F)[N+](=O)[O-]
InChI InChI=1S/C17H16F3N3O5S/c1-9-8-27-16(28-9)2-4-22(5-3-16)15-21-14(24)11-6-10(17(18,19)20)7-12(23(25)26)13(11)29-15/h6-7,9H,2-5,8H2,1H3/t9-/m0/s1
InChI Key GTUIRORNXIOHQR-VIFPVBQESA-N
No information available.
Summary of Clinical Use Click here for help
BTZ-043 has completed a Phase 1/2 clinical trial, as an orally administered monotherapy, in patients with drug-sensitive pulmonary tuberculosis (TB) (NCT04044001). It will also be evaluated as a TB treatment, in combination with bedaquiline or delamanid, in a Phase 2 trial (NCT05926466) that started recruitment in 2023. Two further clinical studies (NCT06114628, NCT05382312) will assess BTZ-043 as part of novel TB drug regimens.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04044001 BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA) Phase 1/Phase 2 Interventional Ludwig-Maximilians - University of Munich
NCT05926466 BTZ-043 Dose Evaluation in Combination and Selection Phase 2 Interventional Ludwig-Maximilians - University of Munich
NCT06114628 Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Phase 2 Interventional University College, London
NCT05382312 Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in Combination With Delamanid or Bedaquiline, Delamanid in Combination With Bedaquiline, or Standard of Care in Male and Female Participants Aged 18 to 65 Years With Pulmonary Tuberculosis Phase 2 Interventional GlaxoSmithKline